Search Blog
Categories
June 2018
M T W T F S S
« May   Jul »
 123
45678910
11121314151617
18192021222324
252627282930  

Tags

Meson Capital and Argonne Capital Group offer $3.75 per share for InfuSystem

ACCESSWIRE

By Meson Capital Partners LLC

  • Calls on Board to Act in the Best Interest of Shareholders in Evaluating Going-Private Transaction
  • Believes Strategic Review is Necessary to Maximize Value Creation
  • Nominates Slate of Highly Qualified Director Candidates for Election at the Upcoming Annual Meeting to Address the Challenges and Opportunities Facing the Company

SAN FRANCISCO, CA / ACCESSWIRE / June 25, 2018 / Meson Capital Partners LLC (together with its affiliates, “Meson”), a 9.8% shareholder of InfuSystem Holdings, Inc. (NYSE American: INFU, the “Company” or “InfuSystem”), announced that on June 15, 2018 it and Argonne Capital Group, LLC (“Argonne”) sent the Company’s board of directors (the “Board”) a bid letter offering to purchase the Company common stock Meson does not currently own for a price of $3.75 per share, a 56% premium to unaffected stock price prior to the 13D filing on March 20, 2018. Argonne is a closely-held private investment firm that has successfully deployed over $780 million of equity since inception.

Meson and Argonne believe this offer presents an excellent opportunity for Company shareholders to realize an attractive, all-cash premium for their shares at a favorable valuation in a challenging operating environment. The proposed all-cash offer of $3.75/share represents a valuation of 11x EV/EBITDA and 8.3x EV/Adjusted EBITDA, which is a higher valuation multiple than InfuSystem has traded at as a standalone public company and is also a significant premium to the 52-week high price. Under the current leadership of Gregg Lehman, since May 2015, InfuSystem’s Adjusted EBITDA has declined from $16.4m to $13.1m and the stock price has declined from $3.20 to $2.40 prior to the 13D filing on March 20, 2018. Moreover, given the disproportionate burden of public company reporting (both financial and with management resources), Meson and Argonne do not believe it is in the best interest of shareholders for InfuSystem to continue as a public company.

On June 19, 2018, the Board rejected this bid claiming the Company was “not for sale.” Meson and Argonne believe that shareholders have a right to a voice in determining if their Company is for sale. To ensure that InfuSystem’s shareholders have a voice in determining the Company’s future, Meson reserved its rights by nominating highly-qualified director candidates for election at the 2018 annual meeting of stockholders. Meson believes its nominees bring a fresh perspective and, if elected, would be better situated to objectively consider potential strategic transactions.

The full text of Meson’s and Argonne’s bid letter, including the conditions, can be viewed at the following link:

https://www.sec.gov/Archives/edgar/data/1337013/000092189518001938/ex991to13da409013003_061518.htm

Meson has filed a preliminary proxy statement with the SEC which can be viewed at the following link:

https://www.sec.gov/Archives/edgar/data/1337013/000092189518001999/prec14a09013003_06222018.htm

Meson’s nominees include, in alphabetical order:

Mohamed Alkady

  • Co-founder and President of Hart, Inc., a health technology company founded in 2012, to improve the ways in which people inside and outside of the healthcare industry access and engage with health data.
  • Advisor to K5 Ventures, a venture capital firm specializing in early stage growth capital investments, where he advised startups in the technology and healthcare space.

Daniel A. Balda, M.D.

  • Executive Chairman of Medicomp Inc. (“Medicomp”), a developer and manufacturer of ambulatory heart-monitoring systems.
  • Previously held the role of President and Chief Executive Officer at Medicomp and during his tenure he oversaw a strategic merger with United Therapeutics Corporation (UTHR) and led the launch of over a dozen FDA-approved medical products and authored multiple patents.

Bryan Boches

  • Chief Executive Officer and a member of the board of directors of Safe Catch, a food technology firm he founded in December 2014.
  • Former Managing Director, with Medley Capital Corporation (MCC), an investment firm, where he sourced and managed private debt and equity investments in the middle market, and served as a corporate and M&A investment banker with Morgan Stanley.

Richard Linder

  • Founder and former Chairman of the board of directors and Chief Executive Officer of Physicians Care Alliance, LLC, a clinical skin care company that develops professional chemical peels and advanced topical treatments and also educates healthcare professionals.
  • Serves on the board of directors of several start-up companies.

Asha Saxena

  • Founder, Chief Executive Officer and a member of the board of directors of ACULYST Corp., an e-commerce healthcare data analytics firm.
  • Founded and served as President and Chief Executive Officer of Future Technologies, Inc., an international data management solutions firm that specializes in providing management and technology consulting around business intelligence and data warehousing at Fortune 1000 companies in the United States.

Investor Contact

Ryan Morris
rmorris@mesoncapital.com
415-322-0386

SOURCE: Meson Capital Partners LLC

ReleaseID: 503100